How to combat tuberculosis in the year 2000?

Respiration

Volumn 65, Issue 6, 1998, Pages 423-431

  Rieder, Hans L ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BCG VACCINE; CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; CATTLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA PROBE; GENE AMPLIFICATION; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPUTUM ANALYSIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0031754033     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029309     Document Type: Review

References (142)

1. Yajko DM, Nassos PS, Sanders CA, Madej JJ, Hadley WK: High predictive value of the acid-fast smear for Mycobacterium tuberculosis despite the high prevalence of Mycobacterium avium complex in respiratory specimens. Clin Infect Dis 1994;19:334-336.
2. Shaw JB, Wynn-Williams N: Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954;69:724-732.
3. Grzybowski S, Barnett GD, Styblo K: Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975;50:90-106.
4. van Geuns HA, Meijer J, Styblo K: Results of contact examination in Rotterdam, 1967-1969. Bull Int Union Tuberc 1975;50:107-121.
5. Krebs W: Die Fälle von Lungentuberkulose in der aargauischen Heilstätte Barmelweid aus den Jahren 1912-1927. Beitr Klin Tuberk Spezif Tuberkuloseforsch 1930;74:345-379.
6. Raviglione MC, Snider DE Jr, Kochi A: Global epidemiology of tuberculosis: Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-226.
7. Urbanczik R: Present position of microscopy and of culture in diagnostic mycobacteriology. Zentralbl Bakteriol Hyg A 1985;260:81-87.
8. Paramasivan CN, Narayana ASL, Prabhakar R, Rajagopal MS, Somasundaram PR, Tripathy SP: Effect of storage of sputum specimens at room temperature on smear and culture results. Tubercle 1983;64:119-124.
9. Smid I, Salfinger M, Vurma-Rapp U: The use of radiometric tests in the speciation of mycobacteria: A review. Zentralbl Bacteriol 1992; 276:493-501.
10. Ellner PD, Kiehn TE, Cammarata R, Hosmer M: Rapid detection and identification of pathogenic mycobacteria by combining radiometric and nucleic acid probe methods. J Clin Microbiol 1988;26:1349-1352.
11. Shoemaker SA, Fisher JH, Scoggin CH: Techniques of DNA hybridization detect small numbers of mycobacteria with no cross-hybridization with nonmycobacterial respiratory organisms. Am Rev Respir Dis 1985;131:760-763.
12. Pfyffer GE: Amplification techniques: Hope or illusion in the direct detection of tuberculosis? Med Microbiol Lett 1994;3:335-347.
13. Noordhoek GT, Kolk AHJ, Bjune G, Catty D, Dale JW, Fine PEM, Godfrey-Faussett P, Cho SN, Shinnick T, Svenson SB, Wilson S, van Embden JDA: Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: A blind comparison study among seven laboratories. J Clin Microbiol 1994;32:277-284.
14. Noordhoek GT, van Embden JDA, Kolk AHJ: Reliability of nucleic acid amplification for detection of Mycobacterium tuberculosis: An international collaborative quality control study among 30 laboratories. J Clin Microbiol 1996; 34:2522-2525.
15. Langhans T: Über Riesenzellen mit wandständigen Kernen in Tuberkeln und die fibröse Form des Tuberkels. Arch Pathol Anat Physiol Klin Med 1868;42:382-404.
16. Bekedam HJ, Boeree M, Kamenya A, Liomba G, Ngwira B, Subramanyam VR, Harries AD: Tuberculous lymphadenitis: A diagnostic problem in areas with high prevalence of HIV and tuberculosis. Trans R Soc Trop Med Hyg 1997; 91:294-297.
17. Bern C, Patil PS, Bharucha H, Namaambo K, Luo N: Importance of human immunodeficiency virus-associated lymphadenopathy and tuberculous lymphadenitis in patients undergoing lymph node biopsies in Zambia. Br J Surg 1996;83:75-78.
18. Bharucha NE, Ramamoorthy K, Sorabjee J, Kuruvilla T: All that caseates is not tuberculosis. Lancet 1996;348:1313.
19. Pecarrère JL, Raharisolo C, Dromigny JA, Aurégan G, Peghini M, de Rotalier P, Richard J, Guyon P, Ravelojaona H, Rakatoarisoa A: A propos de 660 cas de tuberculoses histologiques extra-pulmonaires étudiés à l'Institut Pasteur de Madagascar. Arch Inst Pasteur Madagascar 1995;62:83-89.
20. Grange JM, Laszlo A: Serodiagnostic tests for tuberculosis: A need for assessment of their operational predictive accuracy and acceptability. Bull World Health Organ 1990;68:571-576.
21. Bothamley GH: Serological diagnosis of tuberculosis. Eur Respir J 1995;8(suppl 20):676-688.
22. Rieder HL: Case finding; in Reichman LB, Hershfield ES (eds): Tuberculosis: A Comprehensive International Approach, ed 1. New York, Dekker, 1993, pp 167-182.
23. Fine PEM: Variation in protection by BCG: Implications of and for heterologous immunity. Lancet 1995;346:1339-1345.
24. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F: Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature. JAMA 1994;271:698-702.
25. Smith PG: BCG vaccination; in Davies PDO (ed): Clinical Tuberculosis, ed 1. London, Chapman & Hall, 1994, pp 297-310.
26. Stanford JL, Shield MJ, Rook GAW: How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 1981;62:55-67.
27. Smith D, Reeser P, Musa S: Does infection with environmental mycobacteria suppress the protective response to subsequent vaccination with BCG? Tubercle 1985;66:17-23.
28. Behr MA, Small PM: Has BCG attenuated to impotence? Nature 1997;389:133-134.
29. Grzybowski S: Epidemiology of tuberculosis and the role of BCG. Clin Chest Med 1989;1: 175-187.
30. Rouillon A, Waaler H: BCG vaccination and epidemiological situation. Adv Tuberc Res 1976;19:64-126.
31. ten Dam HG, Hitze KL: Does BCG vaccination protect the newborn and young infants? Bull World Health Organ 1980;58:37-41.
32. Anonymous: Summary, conclusions, and recommendations from the International Workshop on Research towards Global Control and Prevention of Tuberculosis: With an Emphasis on Vaccine Development. J Infect Dis 1988; 158:248-253.
33. Bloom BR: New approaches to vaccine development. Rev Infect Dis 1989;11:460-466.
34. Kaufmann SHE: Vaccines against tuberculosis: The impact of modern biotechnology. Scand J Infect Dis 1990;76:54-59.
35. Kaufmann SHE, Hess J: Rational design of antituberculosis vaccines: Impact of antigen display and vaccine localization. Biologicals 1997;25:169-173.
36. Lowrie DB, Tascon RE, Colston MJ, Silva CL: Towards a DNA vaccine against tuberculosis. Vaccine 1994;12:1537-1540.
37. Lowrie DB, Silva CL, Colston MJ, Ragno S, Tascon RE: Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 1997;15: 834-838.
38. Malin AS, Young DB: Designing a vaccine for tuberculosis. Unravelling the tuberculosis genome - can we build a better BCG? Br Med J 1996;312:1495.
39. Orme IM: Progress in the development of new vaccines against tuberculosis. Int J Tuberc Lung Dis 1997;1:95-100.
40. Bradbury J: M. tuberculosis genome to be sequenced. Lancet 1996;347:890.
41. Zorini AO: Sul nuovo metodo di chemioprofilassi antitubercolare mediante isoniazide. Riv Tuberc Mal Appar Respir 1956;4:403-437.
42. Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis: A general review. Adv Tuberc Res 1969;17:28-106.
43. American Thoracic Society, Centers for Disease Control, American Academy of Pediatrics: Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-1374.
44. International Union against Tuberculosis Committee on Prophylaxis: Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT Trial. Bull World Health Organ 1982;60: 555-564.
45. Snider DE, Caras GJ, Koplan JP: Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy. JAMA 1988; 255:1579-1583.
46. Anonymous: Chemoprophylaxis for tuberculosis. Tubercle 1981;61:69-72.
47. Rieder HL, Cauthen GM, Comstock GW, Snider DE Jr: Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989;11:79-98.
48. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH: A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550.
49. Leroy V, Msellati P, Lepage P, Batungwanayo J, Hitimana DG, Taelman H, Bogaerts J, Boineau F, van de Perre P, Simonon A, Salamon R, Dabis F: Four years of natural history of HIV-1 infection in African women: A prospective cohort study in Kigali (Rwanda), 1988-1993. J Acquir Immune Defic Syndr 1995;9: 415-421.
50. Dupon M, Texier-Maugein J, Leroy V, Senthilhes A, Pellegrin JL, Morlat P, Ragnaud JM, Chêne G, Dabis F: Tuberculosis and HIV infection: A cohort study of incidence and susceptibility to antituberculous drugs, Bordeaux, 1985-1993. AIDS 1995;9:577-583.
51. Ferreira MMC, Ferrazoli L, Palaci M, Salles PS, Medeiros LA, Novoa P, Kiefer CR, Schechtman M, Kritski AL, Johnson WD, Riley LW, Ferreira OC Jr: Tuberculosis and HIV infection among female inmates in São Paulo, Brazil: A prospective cohort study. J Acquir Immune Defic Syndr 1996;13:177-183.
52. Addington WW: Patient compliance: The most serious remaining problem in the control of tuberculosis in the United States. Chest 1979; 76:741-743.
53. Sumartojo E: When tuberculosis treatment fails: A social behavioral account of patient adherence. Am Rev Respir Dis 1993;147: 1311-1320.
54. Brummer DL, Comstock GW, Davey W, Dubin IN, Ipsen J, Meade GM, Millar JD, Mosley JW, Sartwell PE: Isoniazid and liver disease. Am Rev Respir Dis 1971;104:454-459.
55. Geiseler PJ, Nelson KE, Crispen RG: Tuberculosis in physicians: Compliance with preventive measures. Am Rev Respir Dis 1987; 135:3-9.
56. Nolan CM, Roll L, Goldberg SV, Elarth AM: Directly observed isoniazid preventive therapy for released jail inmates. Am J Respir Crit Care Med 1997;155:583-586.
57. Pilote L, Tulsky P, Zolopa AR, Hahn JA, Schecter GF, Moos AR: Tuberculosis prophylaxis in the homeless: A trial to improve adherence to referral. Arch Intern Med 1996;156: 161-165.
58. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr: Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272.
59. Whalen CC, Johnson JL, Okwera A, Horn DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-808.
60. Hawken MP, Meme HK, Chakaya JM, Morris JS, Githui WA, Juma ES, Odhiambo JA, Thiong'o LN, Kimari JN, Ngugi EN, Bwayo JJ, Gilks CF, Plummer FA, Porter JDH, Nunn PP, McAdam KPWJ: Isoniazid preventive therapy for tuberculosis in HIV-1 infected adults: Results of a randomized controlled trial. AIDS 1997;11:875-882.
61. Aisu T, Raviglione MC, Van Praag E, Eriki P, Narain JP, Barugahare L, Tembo G, McFarland D, Engwau FA: Preventive chemotherapy for HIV-associated tuberculosis in Uganda: An operational assessment at a voluntary counselling and testing centre. AIDS 1995;9:267-273.
62. Geiter LJ, O'Brien RJ: Conference on new approaches for tuberculosis preventive therapy. J Infect Dis 1987;156:536-537.
63. Hong Kong Chest Service/Tuberculosis Research Centre, Madras Medical Research Council, British Medical Research Council: A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
64. Lecoeur HF, Truffot-Pernot C, Grosset JH: Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193.
65. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, Smith PJ, Carson ML, Geiter LJ: Rifampin preventive therapy for tuberculosis infection: Experience with 157 adolescents. Am J Respir Crit Care Med 1997;155:1735-1738.
66. Crofton J: Chemotherapy of pulmonary tuberculosis. Br Med J 1959;i:1610-1614.
67. Crofton J: The contribution of treatment to the prevention of tuberculosis. Bull Int Union Tuberc 1962;32:643-653.
68. Hill AB: Memories of the British Streptomycin Trial in Tuberculosis: The first randomized clinical trial. Contrib Clin Trials 1990;11:77-79.
69. Marshall G, Blacklock JWS, Cameron C, Capon NB, Cruickshank R, Gaddum HJ, Heaf FRG, Hill AB, Houghton LE, Hoyle JC, Raistnck H, Scadding JG, Tytler WH, Wilson GS, Hart PD: Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council Investigation. Br Med J 1948;2:769-783.
70. Fox W: Whither short-course chemotherapy? Br J Chest 1981;75:331-357.
71. British Thoracic Association: A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: Results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 1982;126:460-462.
72. East African Medical Research Council. British Medical Research Council: Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report: Third East African/British Medical Research Council Study. Tubercle 1980;61:59-69.
73. Chan SL, Yew WW, Ma WK, Girling DJ, Aber VR, Felmingham D, Allen BW, Mitchison DA: The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis 1992;73:33-38.
74. Blaschke TF, Skinner MH: The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996; 22(suppl 1):15-22.
75. Hong Kong Chest Service, British Medical Research Council: A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis 1992;73:59-67.
76. McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, Fourie PB: Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154:1462-1467.
77. Dhillon J, Dickinson GM, Guy JA, Ng TK, Mitchison DA: Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber Lung Dis 1992;73:116-123.
78. Mor N, Simon B, Mezo N, Heifets L: Comparison of activities of rifapentin and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother 1995;39:2073-2077.
79. O'Brien RJ: Clinical studies of new rifamycins for the treatment and prevention of tuberculosis (abstract). Int J Tuberc Lung Dis 1997; 1(suppl):11.
80. Tam CM, Chan SL, Lam CW, Dickinson JM, Mitchison DA: Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997;1:411-416.
81. Kanyok T: A lesson to be learned. Int J Tuberc Lung Dis 1997;1:490-492.
82. Vernon A, Villarino E, O'Brien R for the USPHS Study 22 Rifapentine Trial Group: Relapse with rifampin monoresistant TB (RMR-TB) in HIV-positive TB patients treated with a once-weekly rifapentine-containing regimen (abstract). Int J Tuberc Lung Dis 1997; 1(suppl):551-552.
83. Neu HC: New macrolide antibiotics: Azithromycin and clarithromycin. Ann Intern Med 1992;116:515-517.
84. Luna-Herrera J, Reddy VM, Daneluzzi D, Gangadharam PRJ: Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995;39:2692-2695.
85. Heifets LB, Lindholm-Levy PJ: Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 1987;68:267-276.
86. Gillespie SH, Kennedy N: Early bactericidal activity and sterilizing activity of ciprofloxacin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995;151:921-922.
87. Kaplan JA, Krieff DM: Quinolones for the treatment and prophylaxis of tuberculosis. Ann Pharmacol 1996;30:1020-1022.
88. Cohn DL, Bustreo F, Raviglione MC: Drugresistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin Infect Dis 1997; 24(suppl 1):121-130.
89. World Health Organization: Anti-Tuberculosis Drug Resistance in the World: The WHO/ IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. World Health Organization Document 1997:WHO/ TB/97.229:1-227.
90. Finch D, Beaty D: The utility of a single sputum specimen in the diagnosis of tuberculosis: Comparison between HIV-infected and non-HIV-infected patients. Chest 1997;111: 1174-1179.
91. Blair EB, Brown GL, Tull AH: Computer files and analyses of laboratory data from tuberculosis patients. II. Analyses of six years data on sputum specimens. Am Rev Respir Dis 1976; 113:427-431.
92. Toman K: Tuberculosis Case-Finding and Chemotherapy: Questions and Answers, ed 1. Geneva, World Health Organization, 1979, pp 1-239.
93. Daley CL: Tuberculosis recurrence in Africa: True relapse or re-infection? Lancet 1993; 342:756-757.
94. Godfrey-Faussett P, Githui W, Batchelor B, Brindle R, Paul J, Hawken M, Gathua S, Odhiambo J, Ojoo JC, Gilks C, McAdam K, Stoker N: Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection. Tuber Lung Dis 1994;75:199-202.
95. Lin BT: Reinfection with multidrug-resistant tuberculosis. N Engl J Med 1993;111:811-812.
96. Nardell E, McInnis B, Thomas B, Weidhaas S: Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986;315:1570-1575.
97. Nolan CM: Reinfection with multidrug-resistant tuberculosis. N Engl J Med 1993;329: 811.
98. Raleigh JW, Wichelhausen R: Exogenous reinfection with Mycobacterium tuberculosis confirmed by phage typing. Am Rev Respir Dis 1973;108:639-642.
99. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK: Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-1144.
100. Small PM, Shafer RW, Schoolnik GK: Reinfection with multidrug-resistant tuberculosis. N Engl J Med 1993;329:812.
101. Vynnycky E, Fine PEM: The natural history of tuberculosis: The implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997;119:183-201.
102. Chin DP, Osmond D, Page-Shafer K, Glassroth J, Rosen MJ, Reichman LB, Kvale PA, Wallace JM, Poole WK, Hopewwll PC for the Pulmonary Complications of HIV Infection Study Group: Reliability of anergy skin testing in persons with HIV infection. Am J Respir Crit Care Med 1996;153:1982-1984
103. Graham NMH, Nelson KE, Solomon L, Bonds M, Rizzo RT, Scavotto J, Astemborski J, Vlahov D: Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992;267:369-373.
104. Huebner RE, Villarino ME, Snider DE Jr: Tuberculin skin testing and the HIV epidemic. JAMA 1992;267:409-410.
105. Johnson MP, Coberly JS, Clermont HC, Chaisson RE, Davis HL, Losikoff P, Ruff AJ, Boulos R, Halsey NA: Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 1992; 166:194-198.
106. Pesanti EP: The negative tuberculin test: Tuberculin, HIV, and anergy panels. Am J Respir Crit Care Med 1994;149:1699-1709.
107. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society: Guidelines on the Management of Tuberculosis and HIV Infection in the United Kingdom. Br Med J 1992;304:1231-1233.
108. Crofton J, Chaulet P, Maher D, Grosset J, Harris W, Horne N, Iseman M, Watt B: Guidelines for the Management of Drug-Resistant Tuberculosis. World Health Organization Document 1996;96.210(Rev. 1):1-40.
109. Brudney K, Dobkin J: Resurgent tuberculosis in New York City: Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991;144:745-749.
110. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA: Tuberculosis in New York City. Turning the tide. N Engl J Med 1995;333: 229-233.
111. Enarson DA: Principles of IUATLD Collaborative Tuberculosis Programmes. Bull Int Union Tuberc Lung Dis 1991;66:195-200.
112. Enarson DA: The International Union against Tuberculosis and Lung Disease Model National Tuberculosis Programmes. Tuber Lung Dis 1995;76:95-99.
113. Enarson DA, Rieder HL, Arnadottir T, Trébucq A: in International Union against Tuberculosis and Lung Disease (ed): Tuberculosis Guide for Low-Income Countries, ed 4. Frankfurt, pmi Publishing, 1996, pp 1-65.
114. Kochi A: The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991;72:1-6.
115. World Health Organization: Treatment of tuberculosis: Guidelines for National Programmes, ed 2. World Health Organization Document 1997;97.220:1-66.
116. Murray CJL, Styblo K, Rouillon A: Tuberculosis in developing countries: Burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990;65:2-20.
117. Murray CJL, De Jonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K: Cost-effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991;338:1305-1308.
118. Sbarbaro JA: Compliance: Inducements and enforcements. Chest 1979;76:750-756.
119. Sbarbaro JA: Public health aspects of tuberculosis: Supervision of therapy. Clin Chest Med 1980;1:253-263.
120. Burman WJ, Dalton CB, Cohn DL, Butler JRG, Reves RR: A cost-effectiveness analysis of directly observed therapy vs. self-administered therapy for treatment of tuberculosis. Chest 1997;112:63-70.
121. Chaulck CP, Moore-Rice K, Rizzo R, Chaisson RE: Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995;274:945-951.
122. El-Sadr W, Medard F, Barthaud V: Directly observed therapy of tuberculosis: The Harlem Hospital experience, 1993. Am J Public Health 1996;86:1146-1149.
123. Fujiwara PI, Larkin C, Frieden TR: Directly observed therapy in New York City: History, implementation, results, and challenges. Clin Chest Med 1997;18:135-148.
124. Moore RD, Chaulck CP, Griffiths R, Cavalcante S, Chaisson RE: Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996;154:1013-1019.
125. Morse DI: Directly observed therapy: Spend now or pay later. Br Med J 1996;312:719-720.
126. Rolfe LM, Gannon ME, Bintley K, Millard FJC: A programme of directly observed therapy for tuberculosis in London. Int J Tuberc Lung Dis 1997;1:482.
127. Salomon N, Perlman DC, Rubenstein A, Mandelman D, McKinley FW, Yancovitz SR: Implementation of universal directly observed therapy at a New York City hospital and evaluation of an out-patient directly observed therapy program. Int J Tuberc Lung Dis 1997;1:397-404.
128. Weis SE: Universal directly observed therapy: A treatment strategy for tuberculosis. Clin Chest Med 1997;18:155-163.
129. Rieder HL: Opportunity for exposure and risk of infection: The fuel for the tuberculosis pandemic. Infection 1995;23:1-4.
130. Rieder HL: Epidemiology of tuberculosis in Europe. Eur Respir J 1995;8(suppl 20):620-632.
131. Bhatti N, Law MR, Morris JK, Halliday R, Moore-Gillon J: Increasing incidence of tuberculosis in England and Wales: A study of the likely causes. Br Med J 1995;310:967-969.
132. McKenna MT, McGray E, Onorato I: The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med 1995;332:1071-1076.
133. Zuber PLF, McKenna MT, Binkin NJ, Onorato IM, Castro KG: Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997;278:304-307.
134. Rieder HL, Zellweger JP, Raviglione MC, Keizer ST, Migliori GB: Tuberculosis control in Europe and international migration: Report of a European Task Force. Eur Respir J 1994;7:1545-1553.
135. Tala E: Tuberculosis care in foreigners: Ethical considerations. Eur Respir J 1994;7: 1395-1396.
136. Singh NB, Singh EK, Singh HL, Singh YI: Tuberculosis/HIV co-infection in India's north-eastern states. J Infect 1993;26:344-345.
137. Yanai H, Uthaivoravit W, Panich V, Sawanpanyalert P, Chaimanee B, Akarasewi P, Limpakarnjanarat K, Nieburg P, Mastro TD: Rapid increase in HIV-related tuberculosis, Chiang Rai, Thailand, 1990-1994. AIDS 1996;10:527-531.
138. Young KY, Cheong I: A study of Malaysian drug addicts with human immunodeficiency virus infection. Int J STD AIDS 1997;8:118-123.
139. Richner B, Laurent D, Sunnarat Y, Bee D, Nadal D: Spread of HIV-1 to children in Cambodia. Lancet 1997;349:1451-1452.
140. Linh PD: La tuberculose chez les sujets infectés par le VIH àHô Chi Minh-Ville. Cah Santé 1996;6:74.
141. Lindan CP, Lieu TX, Giang LT, Lap VD, Thuc NV, Lurie P, Mandel JS: Rising HIV infection rates in Ho Chi Minh City herald emerging AIDS epidemic in Vietnam. AIDS 1997;11(suppll):5-13.
142. Narain JP, Raviglione MC, Kochi A: HIV-associated tuberculosis in developing countries: Epidemiology and strategies for prevention. World Health Organization Document 1992:WHO/TB/92.166:1-21.